eligibility_summary
Include: ≥18, ECOG 0–1 (2 if AML), adequate organs. r/r TCL (MF/SS ≥IIB ≥2L, PTCL ≥1L, ALCL ALK− ≥1L, ALK+ ≥2L), r/r BCL ≥2L incl anti‑CD20+anthracycline (MCL ≤5L incl A/B, anti‑CD20, BTKi), or AML after ≥1L (excludes APL, BCR‑ABL+, therapy‑related/genetic). Exclude: prior anti‑CD70, CNS disease, active infection, HIV/HBV/HCV, recent anticancer tx, immunodeficiency/autoimmune, prior solid organ/allo‑SCT (AML post‑HSCT allowed ≥3 mo, off IS, no GvHD), prior CD19 CAR‑T ≤6 mo.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06492304 tests CTX131, an allogeneic, gene-edited cellular immunotherapy: CD70-directed CAR T cells engineered ex vivo with CRISPR-Cas9 (biological/cell therapy). Given by IV after lymphodepleting chemotherapy. Mechanism: donor T cells expressing an anti-CD70 chimeric antigen receptor recognize and kill CD70-positive malignant cells via CAR-mediated T‑cell cytotoxicity, CRISPR editing is used to generate the allogeneic product. Targets/pathways: CD70 on tumor cells (implicating the CD70/CD27 axis) across T‑cell lymphoma, B‑cell lymphoma, and AML, engages T‑cell activation and cytolytic pathways against CD70-expressing hematologic malignancies.